CellSource Co

CellSource Co Current Liabilities

The Current Liabilities of CellSource Co (4880.T) as of Oct 27, 2026 is 495.81 M JPY. In the previous year, Current Liabilities was 527.09 M JPY — a change of -5.93% (lower).

Current Liabilities

495.81 MJPY

YoY

-5.93%

Last updated:

Current Liabilities of CellSource Co is 2025 495.81 M JPY. Current Liabilities of CellSource Co was 2024 527.09 M JPY. It decreases by -5.93% lower compared to the previous year.

The CellSource Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
211.58 M JPY
Jan 1, 2019
229.81 M JPY
Jan 1, 2020
283.75 M JPY
Jan 1, 2021
474.81 M JPY
Jan 1, 2022
542.93 M JPY
Jan 1, 2023
504.78 M JPY
Jan 1, 2024
527.09 M JPY
Jan 1, 2025
495.81 M JPY
The CellSource Co Current Liabilities history
YEARCurrent LiabilitiesYoY
495.81 MJPY-5.93%
527.09 MJPY+4.42%
504.78 MJPY-7.03%
542.93 MJPY+14.35%
474.81 MJPY+67.33%
283.75 MJPY+23.47%
229.81 MJPY+8.62%
211.58 MJPY+210.33%
68.18 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Current Liabilities of CellSource Co is 495.81 M JPY in 2025.

Current Liabilities of CellSource Co changed from 527.09 M JPY to 495.81 M JPY, representing a -5.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities CellSource Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's CellSource Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — CellSource Co

All Key Metrics — CellSource Co